Lykos CEO to depart after FDA rejection, layoffs | BioPharma Dive
Lykos Therapeutics CEO Amy Emerson to step down after FDA rejection of MDMA therapy aid approval. Michael Mullette appointed interim CEO. Company plans to cut 75% of workforce and resubmit MDMA approval application.
Reference News
Lykos Therapeutics reshuffles senior management after FDA rejection of MDMA-AT for PTSD, appointing Michael Mullette as interim CEO and Dr. David Hough as CMO. The company focuses on regulatory engagement and clinical development, with Mullette and Hough bringing extensive pharma experience. Amy Emerson steps down as CEO, transitioning to an advisory role, marking Lykos' shift from its MAPS roots towards medicalizing MDMA.
Lykos Therapeutics CEO Amy Emerson steps down, interim CEO Michael Mullette appointed. Emerson to remain as senior advisor. Lykos faces FDA rejection for MDMA therapy, plans resubmission. Company also names David Hough as CMO and lays off 75% of workforce.
Lykos Therapeutics CEO Amy Emerson to step down after FDA rejection of MDMA therapy aid approval. Michael Mullette appointed interim CEO. Company plans to cut 75% of workforce and resubmit MDMA approval application.